thrombocytopenia 6
MONDO:0014837
A syndromic constitutional thrombocytopenia caused by a variation in the SRC gene, characterized by congenital thrombocytopenia, small platelets, and an increased bleeding tendency beginning in infancy or childhood. Affected individuals show impaired megakaryocyte maturation, reduced proplatelet formation, and altered cytoskeletal organization in patient-derived megakaryocytes, consistent with dysregulated SRC kinase signaling. Platelet function studies show variable but generally mild platelet defects, with bleeding phenotypes ranging from easy bruising to mucocutaneous bleeding.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
thrombocytopenia 6
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.